STAGE IIIB BLADDER CANCER AJCC V8
Clinical trials for STAGE IIIB BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIB BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 07:03 UTC
-
New drug combo shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis early-phase trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific changes in the FGFR2/3 genes. The study includes about 24 adults whose cancer worsened after standard chemotherapy. …
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Can a gene test tell who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 06:51 UTC